Our new paper is out: Network pharmacology insights into Major Depressive Disorder

We are excited to share our latest research article "Network pharmacology of cellular targets in major depressive disorder and differential mechanisms of fluoxetine, ketamine and esketamine", recently published in the Computational and Structural Biotechnology.

This study, conducted in collaboration with Silvia Tapia-Gonzalez and Josué García Yagüe from CEU San Pablo University (Spain), explores the molecular mechanisms underlying Major Depressive Disorder (MDD).

Using a network pharmacology approach, we identified key druggable targets (OPRM1, EGFR, and GSK3B) and highlighted NFKB as a central node linking inflammation, synaptic plasticity, and neuronal metabolism. These findings offer promising avenues for optimizing therapeutic efficacy and guiding future treatment strategies.

Read the full open-access paper here: https://pmc.ncbi.nlm.nih.gov/articles/PMC12810504/